# Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis

> **NCT01064401** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 1841 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** BIIB019 (Daclizumab High Yield Process)
- **DRUG:** Interferon beta-1a Placebo
- **BIOLOGICAL:** Interferon beta-1a
- **DRUG:** Daclizumab High Yield Process Placebo

## Key facts

- **NCT ID:** NCT01064401
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2014-03
- **Final completion:** 2014-07
- **Target enrollment:** 1841 (ACTUAL)
- **Last updated:** 2016-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01064401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01064401, "Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01064401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*